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Research Article
Intrathecal administration of AYX2
DNA decoy produces a long-term pain
treatment in rat models of chronic pain
by inhibiting the KLF6, KLF9, and KLF15
transcription factors
Julien Mamet1, Michael Klukinov2, Scott Harris1, Donald
C Manning1, Simon Xie3, Conrado Pascual3, Bradley K Taylor4,
Renee R Donahue4 and David C Yeomans2
Abstract
Background: Nociception is maintained by genome-wide regulation of transcription in the dorsal root ganglia—spinal cord
network. Hence, transcription factors constitute a promising class of targets for breakthrough pharmacological interventions
to treat chronic pain. DNA decoys are oligonucleotides and specific inhibitors of transcription factor activities. A metho-
dological series of in vivo–in vitro screening cycles was performed with decoy/transcription factor couples to identify targets
capable of producing a robust and long-lasting inhibition of established chronic pain. Decoys were injected intrathecally and
their efficacy was tested in the spared nerve injury and chronic constriction injury models of chronic pain in rats using
repetitive von Frey testing.
Results: Results demonstrated that a one-time administration of decoys binding to the Kruppel-like transcription factors
(KLFs) 6, 9, and 15 produces a significant and weeks–month long reduction in mechanical hypersensitivity compared to
controls. In the spared nerve injury model, decoy efficacy was correlated to its capacity to bind KLF15 and KLF9 at a specific
ratio, while in the chronic constriction injury model, efficacy was correlated to the combined binding capacity to KLF6 and
KLF9. AYX2, an 18-bp DNA decoy binding KLF6, KLF9, and KLF15, was optimized for clinical development, and it demon-
strated significant efficacy in these models.
Conclusions: These data highlight KLF6, KLF9, and KLF15 as transcription factors required for the maintenance of chronic
pain and illustrate the potential therapeutic benefits of AYX2 for the treatment of chronic pain.
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Introduction
Chronic pain stems, in part, from an acquired and main-
tained pathologic sensitization of the dorsal root gang-
lion (DRG)—spinal cord network. Microarray
experiments revealed that sensitization is maintained by
sequential waves of gene regulation.1–3 Those can impact
up to 400 genes at a time across a broad spectrum of
gene categories, including genes controlling the tran-
scriptional, homeostatic, metabolic, oxidative, protein
turnover, trafficking, structural, and communicative
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states of neurons and glia.1,4–15 Dynamically, these
expression changes are launched early on by immedi-
ate-early transcription factors like early growth factor 1
(EGR1) following an injury and maintained over time by
delayed transcription factor networks.16–18
Transcription factors directly regulate gene expres-
sion, with a single factor regulating the expression of
many genes. As such, they represent therapeutic targets
with the unique opportunity to simultaneously influence
the activity of a high number of genes supporting noci-
ception and influence the long-term course of pain. From
a therapeutic prospective, transcription factors can be
inhibited by DNA decoys or synthetic double-stranded
oligonucleotides that mimic their binding sites on the
genome (Figure 1). In a prior study, we demonstrated
that locally blocking EGR1 activity with an EGR1-
specific decoy named AYX1 around the time of an
injury prevents the development of long-term pain in
rats.18 AYX1 is currently under clinical development
(clinicaltrial.gov identifier: NCT02807428).
We hypothesized that a brief inhibition of select
delayed transcription factors maintaining the stability
of transcriptomes associated with pathologic nociception
could reduce pain for long periods of time. An under-
lying assumption was that once those transcriptomes are
destabilized, they are unlikely to spontaneously reinitiate
because their occurrence depends on earlier transcrip-
tional waves that have resolved in mature pain states.
To test this hypothesis, we designed 35 decoys against
single factors or family of factors with the potential to be
involved in the maintenance of pathologic nociception.
A screening method was implemented to test the decoys
in vivo for their capacity to reduce mechanical hypersen-
sitivity in the spared nerve injury (SNI) model of chronic
neuropathic pain. The SNI model was chosen for its
well-characterized neuropathic pain features and prior
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Figure 1. Illustration of DNA decoy action in chronic pain treatment. In a chronic pain state (a), TFs involved in the maintenance of
neuronal sensitization bind to specific DNA sequences (TF binding site) on the genome of DRG and spinal cord cells and upregulate or
downregulate (pathologic nociception regulation) hundreds of genes (sensitization-related genes). As a result, the genomic status of those
cells is shifted toward a pathologic set of gene regulations that are responsible for the maintenance of neuronal sensitization and chronic
pain (transcriptomes associated with long-term neuronal sensitization). DNA decoys (green) are synthetic, double-stranded oligo-
nucleotides that mimic the binding sites of their TF target on the genome. The local intrathecal administration of specific DNA decoys (b)
can prevent the binding of TF to their binding sites on the genome and interrupt the maintenance of the transcriptomes associated with
long-term neuronal sensitization, resetting gene regulation toward a normal transcriptome and a normal neuronal sensitivity.
TF: transcription factor.
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demonstration with AYX1 that it can be sensitive to an
intrathecal decoy treatment.18 In the light of a high
number of decoys to test, screening throughput and
animal use considerations, the decoy attrition strategy
relied on initially detecting potential efficacy in small
groups of animals and assessing accuracy and reprodu-
cibility of those effects by their independent reproduction
through multiple screening phases. Ultimately, efficacy
reproduced through the screening was confirmed in
larger groups of animals. Out of the screen, only two
decoys produced a significant and long-term reduction
in mechanical hypersensitivity, both targeting the
Kruppel-like factors (KLFs) family. Iterative in vivo–
in vitro testing cycles identified the specific KLF factors
and decoy binding behaviors associated with each
decoy’s activity. AYX2 was developed using this know-
ledge as a drug candidate with the potential to provide
long-term reduction of chronic pain in patients with a
single administration.
Methods
Decoys and vehicles
Decoys were designed at Adynxx, except for KLF refer-
ence decoys 1 and 2, which were selected from the litera-
ture (supplemental Table 1).19,20 Sense and antisense
strands of each decoy were manufactured by Invitrogen
(CA), resuspended in Tris- and calcium-based vehicle
formulations, and hybridized at room temperature.
Enzyme-linked immunosorbent assay
Decoy binding to KLFs was measured using a custo-
mized version of a commercial Enzyme-linked immuno-
sorbent assay (ELISA) kit (Affymetrix, CA). Briefly, 12.8
pmoles of KLF biotin-decoy probe were incubated with
15 mg of HELA nuclear protein extracts for KLF1-6,
KLF8-14, and KLF16-17 detection (catalogue # 36010,
Active motif, CA) and HEK290 extracts for KLF15
detection (catalogue # 36033, Active motif, CA). For
KLF7 detection, 0.5 and 1 mg of a recombinant human
KLF7 protein was utilized (Novus, CO). The probe–pro-
tein mix was processed following the kit’s instructions
and the quantity of captured KLF measured with an
antibody-based colorimetric detection in a microplate
reader (OD450 nm). Primary antibodies were commercial
antibodies validated for specificity by suppliers and char-
acterized for ELISA or assays detecting the native,
human form of their target (e.g., gel shift). They are
listed in supplemental Table 2. The secondary antibody
conjugated to horseradish peroxidase was provided in
the ELISA kit (dilution 1:200). The experimental condi-
tions for assay linearity, specificity, and sensitivity were
determined using KLF decoy 1, the most efficacious KLF
decoy identified during the initial in vivo screening, to
the human form of KLF4, a predominant KLF member
known to bind the KLF consensus binding sites that
were used as a frame to design KLF decoy 1 in silico.
Assay sensitivity was optimized by testing the binding
level of a fixed amount of KLF decoy 1 biotinylated
probe incubated in the presence of crossover quantities
of nuclear protein extracts and KLF4 primary antibody
dilutions. Assay specificity was confirmed by standard
controls previously described for transcription factor
ELISA18,21: (1) nonspecific, background noise correction
using a reaction mix lacking proteins internally for each
individual assay and testing condition, (2) binding com-
petition experiments to the KLF decoy 1 biotin probe
with free, nonbiotinylated KLF decoy 1 competitor, (3)
confirmation of binding by positive control decoys KLF
reference decoys 1 and 2, and (4) confirmation of absence
of binding by two complementary mutant, non-KLF
binding decoys. The expansion of the assay beyond
KLF4 to the other KLFs was performed using the
same amount of nuclear proteins extract (except for
KFL7, see above) and the primary antibody dilution rec-
ommended by the supplier when available or the lowest
practical dilution with specificity measured against the
binding to a mutant decoy.
Animals
A total of 229 Sprague Dawley rats (Harlan Industries,
Livermore, CA), males, 250–300 g, were used. Animal
housing and handling was performed in accordance
with the Animal Care and Use Committees guidelines
of each testing site. Those committees approved all
experiments.
Vehicle and decoy administration
Articles were delivered via a bolus, percutaneous 20 mL
intrathecal injection at the L5–L6 vertebra level as pre-
viously described.18 Throughout the study, decoys were
dosed between 50 and 300 nmoles, which is consistent
with prior work with AYX1 decoy showing that those
doses injected intrathecally in rats are sufficient to pro-
duce a pharmacological effect.18
Behavioral testing
SNI and chronic constriction injury (CCI) models were
performed as described elsewhere.22–24 Rats were habi-
tuated in cages with mesh wire floors for 1 h before von
Frey hairs testing. Calibrated von Frey hairs were
applied with the following pseudorandom pattern: 6, 1,
10, 4, 26, 10, and 8 g. For each testing level, von Frey
hairs were applied five times consecutively to the hind
paw ipsilateral to the injury, and the number of paw
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withdrawals (0 to 5 per level, 0 to 35 in total) was rec-
orded as a response. The time interval between each test-
ing level for a given rat was at least 3min.18
Blinding and randomization
Behavioral experiments were all performed blinded.
Each testing site received blinded article vials, and the
blinding code was revealed to the testing site and experi-
menter only after testing was completed and the data
received. Data were analyzed independently at Adynxx
and at the testing sites, and the analyses were cross-
checked. Animal randomization to treatment groups
was performed before treatment on the day of the first
dosing: animals were distributed in groups so that the
mean von Frey responses were close across testing
groups, targeting within 15% of each other if values
permitted.
Predetermined inclusion and exclusion criteria
Due to the amount of testing required for this work,
appropriate animal model performance and technical
bias avoidance were pursued by predetermining the fol-
lowing inclusion/exclusion criteria derived from prior
experimental work18,25 instead of using sham groups:
(1) threshold for the absence/presence of model-induced
hypersensitivity: animals with von Frey values45 on the
day of the first dosing were excluded since rats can reach
this response level in basal conditions and (2) pain model
performance: if the average von Frey values of vehicle-
treated rats decreased by 50% or more during the first
week following injection, then the entire tested cohort
(vehicle- plus decoy-treated animals) was excluded.
When they occurred, exclusions are listed in the figure
legends, and the number of animals listed per testing
conditions reflects the exclusions.
Statistical analysis
Nonparametric Student’s t test was used to analyze indi-
vidual conditions and whole data distribution compari-
son between experimental conditions using Microsoft
Excel, version 14.4.1. One-way analysis of variance and
Dunnett’s multiple comparison tests were performed
using GraphPad Prism version 7.0 (GraphPad
Software, La Jolla, CA, www.graphpad.com).
Results
Decoys efficacy screening in the SNI model
Thirty-five transcription factors or families of transcrip-
tion factor targets were selected for screening based on
their known function in pain or pain-related biological
systems, such as inflammation or memory and internal
cross-species analysis of selected pain-related gene pro-
moters (Table 1).
Decoys targeting those factors were designed in silico
using response element matrices and binding prediction
software (e.g., TESS, TRANSFAC, JASPAR). Decoys
were grouped in 11 triplexes and one duplex based on the
functionality of their target to increase testing through-
put (TLX, Table 1). The screening was structured in
three sequential phases of attrition: (1) phase 1: identify
triplex/duplex with potential efficacy for reducing mech-
anical hypersensitivity in the SNI model, (2) phase 2:
independent confirmation of their efficacy, and (3)
phase 3: identification of the individual decoys that
carry efficacy. In each phase, articles were injected once
at day 14 (15 in one occurrence) following SNI surgery,
at which point mechanical hypersensitivity was devel-
oped, and once more within 10 days to increase the reli-
ability of tested outcomes. Due to the high number of
decoys to test, phase 1 was performed with n¼ 3 for each
triplex/duplex, and the accuracy of effects was pursued
via their independent reproduction throughout the
screening. This strategy was supported by prior work
with the AYX1 decoy showing that meaningful decoy-
driven pharmacodynamic effects can be detected with
n¼ 3 in the SNI model.18 The triplex/duplex approach
introduced the possibility of interactions between the
effects of decoys when injected together that could
mask the effects decoys could have individually.
Therefore, the choice was made in phase 2, while ‘‘n’’
increased to 5–6 to only seek for trends of efficacy over
using a strict statistical analysis to guide triplex selection.
In that context, the criteria to define trends of efficacy in
phases 1 and 2 were (1) total von Frey hair responses
lower compared to vehicle-treated animals and (2) a
numerical reduction of at least 25% from the baseline
hypersensitivity measured on day 14 for at least two con-
secutive time points. Statistical analysis was then per-
formed for individual decoys testing in phase 3.
Overall, data normalization was an essential tool of the
decoy screening and optimization process that allowed
for a sensitive analysis of data across small groups of
animals, independent testing and laboratories. The cor-
responding raw von Frey data are presented in supple-
mental tables.
In the first phase of the screening, only the effects of
TLX1, TLX4, and TLX5 matched our dual selection
criteria for efficacy, and their effect was tested for
approximately three weeks (Figure 2(a)).
TLX7 and TLX8 showed some potential for efficacy
early on, so they were also followed over three weeks, but
their effects did not meet our dual criteria at the end
(Figure 2(a) and (b)). No trend of effect was suggested
by TLX6, TLX9, TLX10, or TLX11 treatments, which
illustrates the specificity of the triplex/duplex approach
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Table 1. Decoy triplexes and transcription factor targets.
Triplex
number
Screening
decoy
number
Transcription factor target
Functional scope Name Superclass Class Family
Decoy 2 EGR1 Zinc finger Zn finger – C2H2 Developmental/cell
cycle regulator
TLX1 Decoy 4 Immediate early
gene
CEBP Basic domains bZIP CAAT enhancer
Decoy 31 TCF/SRF Beta scaffold MADs box Responders to
external signals
Decoy 5 CREB/ATF Basic domains bZIP CREB
TLX2 Decoy 1 Constitutive factor AP1 Basic domains bZIP AP1
Decoy 9 ETS1/SRF/Elk1 Helix-turn-helix/
beta scaffold
Tryptophan
cluster/MADS
ETS/responder to
external signals
Decoy 26 REST Zinc finger Zn finger – C2H2 Developmental/cell
cycle regulators
TLX3 Decoy 27 Tissue/neuro
differentiation
RUNX Beta scaffold Runt Runt
Decoy 12 HNF1 Helix-turn-helix Homeo domain Homeo domain
Decoy 6 ELf1/POU1F1 Helix-turn-helix Tryptophan cluster ETS
TLX4 Decoy 7 Tissue/neuro
differentiation
ELK1 Helix-turn-helix Tryptophan cluster ETS
Decoy 8 ELK1/ETS1 Helix-turn-helix Tryptophan cluster ETS
Decoy 16 KLFs Zinc finger Zn finger – C2H2 KLF Like
TLX5 Decoy 17 Tissue/neuro
differentiation
KLFs Zinc finger Zn finger – C2H2 KLF Like
Decoy 35 LEF1 Beta scaffold HMG TCF-1
Decoy 18 MAF Basic domain bZIP Maf
TLX6 Decoy 19 Development/cell
differentiation
MEF2 Beta scaffold MADs box Regulator of
differentiation
Decoy 22 Ngfma N/A N/A N/A
Decoy 23 POU2F1/3F/5F Helix-turn-helix Homeo domain POU domain
factors
TLX7 Decoy 24 Development/cell
differentiation
POU4F1 Helix-turn-helix Homeo domain POU domain
factors
Decoy 11 GATA1 Zinc finger Zn finger – Cys4 GATA
Decoy 28 SP1 Zinc finger Zn finger – C2H2 Ubiquitous Factors
TLX8 Decoy 33 Ubiquitous/broad
scope
USF Basic domains bHLH-ZIP Ubiquitous bHLH-
ZIP factors
Decoy 3 CACCC-box
binding factors
N/A N/A N/A
(continued)
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(Figure 2(b)). Finally, the effects of TLX2, TLX3 and
TLX12 suggested a potential aggravation of mechanical
hypersensitivity (Figure 2(b)). In the second phase,
TLX1 and TLX5 but not TLX4 reproduced efficacy by
meeting our dual criteria (Figure 3(a)). TLX8, which
only met the efficacy criteria against vehicle in phase 1,
was also tested here to further assess for the sensitivity of
our approach. Consistent with phase 1, it met only
one predefined criteria for efficacy but not the two
(Figure 3(a)).
TLX1 and TLX5 were then carried into the final
phase of the screening to evaluate the efficacy of their
respective individual decoys. Two hundred nanomoles of
each decoy were injected versus 100 nmoles in their
respective triplex (i.e., maximal dose due to solubility
and dosing volume limits as each triplex contained
three different molecular entities). Individual decoys
from TLX1 only demonstrated a modest efficacy that
was short-lived and that could not be amplified by a
second injection (Figure 3(b)). From TLX5, the two
decoys binding KLF factors, KLF decoys 1 and 2, pro-
duced a robust and long-lasting reduction in mechanical
hypersensitivity that was maintained numerically over
controls until the hypersensitivity from the model started
to resolve 5 weeks after injections (Figure 3(c)). In
contrast, the LEF1 decoy 35 showed a limited efficacy
that was numerically lower than the triplex efficacy
(Figure 3(c)). Interestingly, TLX8, which showed poten-
tial efficacy during the screening, contains a CACCC-box
decoy, which has a consensus site for the SP/KLF family
different from KLF decoy 1 and 2. These results sug-
gested differential KLF binding patterns for the KLF
decoys and raised the question of which KLFs are
involved in chronic pain. Raw von Frey data for each
group and testing phase of the screening are presented in
supplemental Table 3.
Decoy KLF binding patterns
The KLF family includes 17 members, each recognizing
a range of DNA sequences.26,27 KLF decoys 1 and 2 were
designed in silico. To decipher their actual KLF binding
pattern, a KLF ELISA assay was developed to measure
their binding activity against the human forms of the 17
family members (Figure 4(a)–(c)). Binding activities of
KLF decoys 1 and 2 were compared to (1) the
CACCC-box decoy from TLX8, (2) two independent
KLF reference decoys containing complementary ver-
sions of the KLF consensus-binding site selected from
the literature,19,20 and (3) to negative control-mutant
Table 1. Continued
Triplex
number
Screening
decoy
number
Transcription factor target
Functional scope Name Superclass Class Family
TLX9 Decoy 30 Transcription
machinery
TBP Beta-scaffold TATA-binding
proteins
TBP
Decoy 21 NFY Beta-scaffold HMG NFY
Decoy 34 ZFHX3 Helix-turn-helix Homeo domain Homeo domain
plus zinc finger
motifs
TLX10 Decoy 20 Caþþ sensitive NFAT Beta scaffold RHR NFAT
Decoy 15 KCNIP3 E2F hand N/A N/A
Decoy 14 IRF Homeo domain Tryptophan cluster Interferon-regulat-
ing factors
TLX11 Decoy 25 External signal
response
PPAR alpha Zinc finger Zn finger – Cys4 Thyroid hormone
receptor-like
factors
Decoy 13 HSF Helix-turn-helix Heat shock HSF
Decoy 29 Mixed STAT Beta scaffold STAT STAT
TLX12 Decoy 10 ETS1 Helix-turn-helix Tryptophan cluster ETS
Decoy 32 TEAD1 Basic domain bZIP bZIP-PAR
bZIP: basic leucine zipper; bHLH-ZIP: helix-loop-helix/leucine zipper factors; Screening decoy 16: KLF decoy 1; Screening decoy 17: KLF decoy 2; Screening
decoy 3: CACCC-box decoy; neuro: neurological tissue; N/A: not applicable.
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decoys.18 Positive binding was found for at least one
decoy to KLF4, KLF5, KLF6, KLF7, KLF9, KLF12,
KLF15, and KLF16 (Table 2). No relevant binding was
detected for the other KLFs under our testing condi-
tions. Importantly, decoys all presented different KLF
binding patterns (Figure 4(d) and Table 2), consistent
with the different efficacy profiles observed for the
KLF decoys in vivo.
KLF decoys with combined binding to KLF6, KLF9,
and KLF15 treat chronic pain
To identify which KLFs are associated to a decoy’s effi-
cacy for reducing pain and if they differ with the type of
injury, KLF decoy 1 and 2 were tested in parallel to the
CACCC-box decoy and to the two KLF reference decoys
in the SNI (i.e., nerve transection) and CCI models
(i.e., nerve ligature). Two hundred nanomoles of each
decoy were injected at day 14 and 17, similar to the
phase 3 of the screen. In the SNI model, KLF decoy 1
and KLF reference 1 both produced a maximum mech-
anical hypersensitivity reduction of 70%, and their
effect was observed until hypersensitivity was resolving
in controls (Figure 4(e) and supplemental Table 4). KLF
decoy 2 produced efficacy in a similar range in terms of
amplitude and duration, although numerically lower.
The CACCC-box decoy produced an intermediate level
of efficacy that resolved earlier; therefore, its testing was
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Figure 2. Effects of the triplex/duplex in the phase 1 of the decoy screening in the SNI model. Decoys’ performance relating to the dual
efficacy criteria are shown: von Frey values normed on POD 14 values before the first injection (white bars), and von Frey values normed
on vehicle values at each tested day (black curves). Blue dashed lines mark the normed threshold value of 1 to assess decoys performance
(black curves) against vehicle. Red dashed lines mark the normed threshold value of 0.75 (i.e., 25 % reduction) to assess decoys per-
formance (white bars) against POD14 preinjection von Frey values. von Frey values were normalized individually for each rat, and data are
presented as means for each group; corresponding raw von Frey values are presented in supplemental Table 3. The triplexes meeting the
predefined criteria of potential efficacy are shown in (a) while the ones that did not are shown in (b). Each triplex contained 100 nmoles of
each decoy and the duplex TLX12 contained 150 nmoles of each decoy. Dosing occurred once at day 14 (day 15 for TLX10) and day 17
(day 18 for TLX10); n¼ 3 for each triplex/duplex and n¼ 4 for vehicle. This study was performed at the Stanford University.
POD: post-surgery day.
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not pursued beyond day 31. On the other end, KLF ref-
erence decoy 2 was not effective. When examining the
sensitivity of the von Frey hairs affected by the effica-
cious decoys, the entire range was reduced from light
(1 g) to strong mechanical stimuli (26 g) that elicit a
paw withdrawal response even in the absence of an
injury (Figure 4(f)). In the CCI model, the decoys also
produced an array of efficacy patterns, KLF decoys 1 and
2 being most efficacious (supplemental Table 4).
The combined analysis of decoy’s KLF binding pat-
tern and efficacy profiles in the SNI model highlights the
following: (1) KLF9 binding appears to be a prerequisite
to efficacy since KLF reference decoy 2 is the only decoy
to not bind KLF9 and to not show efficacy and
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Figure 3. (a) Effects of TLX1, TLX4, TLX5, and TLX8 in the phase 2 of the decoys’ screening in the SNI model. Triplexes contained 100
nmoles of each decoy and were dosed once at post-surgery day (POD) 14 and 23. (b) Effect of TLX1 and of its individual decoys tested in
parallel in the phase 3 of the screening. t test versus vehicle, *p< 0.05, n¼ 5–6 per group. (c) Effect of TLX5 and of its individual decoys
tested in parallel in the phase 3 of the screening, t test versus vehicle, *p< 0.05, n¼ 3 per group. In all graphs, decoys’ performance relating
to the dual efficacy criteria are shown: von Frey values normed on POD14 preinjection values are displayed as white bars, and von Frey
values normed on vehicle values at each tested day are displayed as black curves. Blue dashed lines mark the normed threshold value of 1 to
assess decoys performance (black curves) against vehicle, red dashed lines mark the normed threshold value of 0.75 (i.e., 25 % reduction)
to assess decoys performance (white bars) against POD14 preinjection von Frey values. von Frey values were normalized individually for
each rat, and data are presented as means for each group; corresponding raw von Frey values are presented in supplemental Table 3. In (b)
and (c) sections, TLX1 and TLX5 contained 100 nmoles of each decoy, individual decoys were dosed at 200 nmoles and injections occurred
once at day 14 and 17. Inclusion/exclusion based on predetermined criteria: two rats in (a) and three rats in (b) did not develop
hypersensitivity following surgery, with POD14 von Frey values 45 and were excluded. The experiment in (c) was performed in two
sequential cohorts of three animals per group with equal representation of testing conditions. All vehicle-treated animals of the first cohort
showed a reduction of von Frey values in the 50% range or below, with an average of 59% reduction between POD14 and POD20 leading
to the exclusion of that cohort (vehicle- plus decoy-treated animals). This study was performed at the Stanford University.
KLF: Kruppel-like transcription factor; POD: post-surgery day.
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Figure 4. (a) KLF ELISA linearity and sensitivity. Increasing amounts of Hela nuclear protein extracts were incubated with a fixed amount
of KLF decoy 1 biotinylated probe (12.5 mmoles) and either 1:1000 (square) or 1:200 (black and white circles, two separate experiments)
dilution of a specific KLF4 antibody. The signal produced by the 1:200 dilution plateaus after 15mg of protein. Regressions of the linear
signal portion for each antibody dilution are shown as dotted line (R2¼ 0.87 and 0.91 and 1:1000 and 1:200, respectively). (b) KLF ELISA
specificity control 1. The specificity of KLF binding is illustrated by the positive binding of reference decoys 1 and 2 to KLF4 and the lack of
binding to KLF4 of two different mutant decoys lacking KLF binding sites. (c) KLF ELISA specificity control 2. Specificity of the assay was
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(2) KLF15 inhibition appears necessary for long-term
efficacy and robust pain reduction as the CACCC-
box decoy, the active decoy with the lowest and short-
est-lived efficacy, does not bind to KLF15 while the other
active decoys do. Similar cross-analysis in the CCI
model, in which KLF decoys 1 and 2 showed a meaning-
ful efficacy and the CACCC-box decoy an intermediary
efficacy level, suggests that (1) an appropriate level of
inhibition of KLF9 is necessary but not sufficient for a
robust efficacy since it is the common denominator
between KLF decoys 1, 2 and the CACCC-box decoy
which present different efficacy levels (the fact that refer-
ence decoy 1 also inhibits KLF9 suggests that another
factor it binds could interfere with its activity), and (2)
KLF6 inhibition is required for a robust and sustained
efficacy since only KLF decoys 1 and 2 have significant
binding to KLF6. Those data suggest that KLF6, KLF9,
and KLF15 cooperate to maintain chronic pain across
the tested injuries, KLF9 and KLF15 in the SNI and
KLF9 and KLF6 in the CCI models.
AYX2 sequence development
KLF decoys 1 and 2 possess a unique ability to reduce
pain by inhibiting KLF6, KLF9, and KLF15 activities.
Those were selected as a basis to generate the sequence of
a therapeutic decoy candidate for the treatment of
chronic pain. The objectives for generating such
sequence were to (1) reduce the sequence size below
25 bp (KLF decoy 1 and 2 are 37 and 29-bp long,
respectively) to achieve appropriate solubility for clinical
dosing (e.g., 110mg/mL similar to AYX1 decoy,
ClinicalTrials.gov identifier NCT02807428) and (2)
maintain binding efficiency (i.e., binding activity
Figure 4. Continued
further demonstrated by the inhibition of KLF4 binding to the biotinylated KLF decoy 1 probe in the presence of increasing amount of free
KLF decoy 1 competitor. This study was performed at Adynxx. (d) Decoys’ KLF binding patterns. Pie graph representation of the pro-
portionate binding of each specific KLF relative to the total binding to all bound KLFs for the corresponding decoy. Binding data significantly
different from the binding level of mutant decoy 1 (p4 0.05), or with a trend of statistical significance (p4 0.1), were used to generate the
graphs (see Table 2), n5 5. This study was performed at Adynxx. (e) Effect of decoys with differential KLF binding patterns in the spared
nerve injury (SNI) model. Meanþ SEM values of normalized total responses to repetitive von Frey hair application for animals groups
treated with vehicle (white triangle), KLF reference decoy 1 (black triangle), KLF reference decoy 2 (black circle), CACCC-box decoy (black
square), KLF decoy 1 (X mark) and 2 (white square) are displayed. Normalization of von Frey hair responses was performed for each rat
individually against its preinjection value measured on post-surgery day 14, and the corresponding raw von Frey values are presented in
supplemental Table 4. Articles were injected intrathecally once on day 14 and 17 (arrows). Testing of KLF decoys 1 and 2 and reference decoy
1, which presented the strongest activity level, was pursued until von Frey values started to resolve from a plateau level toward baseline in
the vehicle group (day 48). Preinjection data before day 14 are combined across groups, 200 nmoles of each decoy or vehicle were injected
once at days 14 and 17 (arrows), t test versus vehicle: *p4 0.05, data distribution over the testing periods: ANOVA, all groups: p< 0.0001,
Dunnett’s multiple comparison test against vehicle: p< 0.0001 for all groups except for KLF ref 2 (p¼ 0.53), n¼ 5 per group. This study was
performed at AfaSci, Inc. (f). Range of effect of the KLF decoys in the SNI model. Meanþ SEM values of response for each individual von
Frey hair out of five stimulations from the day of the first injection until the last day of testing for each decoy plotted from the experiment
displayed in (e) above, ref¼ reference, t test versus vehicle, *p< 0.05, ANOVA, for all groups at each hair level from 6 to 26 g: p< 0.05,
Dunnett’s multiple comparison test against vehicle: zp< 0.05.
KLF: Kruppel-like transcription factor; VF: von Frey hair.
Table 2. Differential KLF binding of decoys.
KLF
KLF KLF CACCC-box Reference Reference Mutant
Decoy 1 Decoy 2 Decoy Decoy 1 Decoy 2 Decoy 1
Member Mn Md SEM Mn Md SEM Mn Md SEM Mn Md SEM Mn Md SEM Mn Md SEM
KFL4 0.172 0.164 0.020 0.245 0.187 0.070 0.376 0.386 0.037 0.531 0.555 0.070 1.157 1.125 0.100 0.118 0.172 0.040
KFL5 0.306 0.292 0.030 0.452 0.466 0.050 0.622 0.496 0.100 0.477 0.503 0.100 1.009 0.990 0.080 0.307 0.275 0.050
KFL6 0.390 0.294 0.070 0.250 0.291 0.040 0.210 0.285 0.068 0.073 0.095 0.030 0.132 0.127 0.040 0.110 0.087 0.050
KFL9 0.216 0.214 0.030 0.195 0.184 0.030 0.176 0.153 0.040 0.148 0.089 0.040 0.206 0.045 0.140 0.002 0.000 0.000
KFL12 0.337 0.317 0.030 0.235 0.236 0.020 0.258 0.252 0.021 0.210 0.220 0.010 0.251 0.254 0.010 0.297 0.276 0.030
KFL15 0.369 0.372 0.010 0.266 0.257 0.040 0.087 0.028 0.066 0.205 0.208 0.010 0.177 0.177 0.010 0.185 0.184 0.000
KFL16 0.230 0.171 0.070 0.185 0.213 0.060 0.212 0.207 0.055 0.206 0.132 0.090 0.302 0.334 0.040 0.169 0.159 0.020
Mean (Mn), median (Md), and SEM binding OD450 values (KLF ELISA) for each decoy to KLF4, KLF5, KLF6, KLF9, KLF12, KLF15, and KLF16 are presented in the
table. Student’s t test versus corresponding mutant decoy binding values: no highlight¼ statistically significant (p4 0.05), blue highlight¼ statistical trend
(p4 0.1), gray highlight¼ not statistically significant (p> 0.1). A hint of binding for KLF7 was detected for KLF decoy 2 and reference decoy 2; however, data could
not be compared to the other KLF as it required using a recombinant version of the human KLF7 protein versus whole nuclear extracts for the other KLFs.
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normalized by decoy size) to KLF6, KLF9, and KLF15
as decoy size decreases. The optimization process was
conducted in two steps: (1) a first set of sequences was
generated and tested to identify families of sequences
with the potential to meet the targeted decoy features
and then (2) a novel set of sequences was derived from
the lead sequence families initially identified to further
improve sequence features.
The binding of each decoy to KLF6, KLF9, and
KLF15 was measured in duplicate and in parallel to
KLF decoys 1 and 2 using the KLF ELISA described
above. When a sequence of interest was identified, its
binding was confirmed independently once or twice
more. Over 30 variant sequences were generated through
this process by fusion, and orientation of the two KLF
binding sites present in KLF decoys 1 and 2, as well as
modifying the sequence and size of their 5’ and 3’ flank-
ing sites. A variety of binding profiles were produced by
those sequences, and six decoys (1.6.2, 1.6.5, 1.9, 2.1, 2.5,
and 2.9) were selected as best matching the predeter-
mined criteria (Table 3).
The effect of a single administration of each of these
decoys was tested in parallel to KLF decoys 1 and 2 in the
SNI and CCI models. Decoys or vehicle were injected on
post-surgery day 14, and their effects were measured up
to day 31, a time point sufficient to discriminate different
efficacy patterns. Results highlighted a spectrum of
decoy efficacy patterns in terms of amplitude and dur-
ation of pain relief across the two models (Figure 5(a)–
(c) and supplemental Table 5). Decoy 1.6.5 was selected
as AYX2 because it has (1) the same efficacy as KLF
decoy 1 in the SNI model and the highest combined effi-
cacy across the SNI and CCI models (Figure 5(a)–(c))
and (2) a short size (18 bp) while maintaining the binding
parameters of its parent KLF decoy 1 (37 bp; Figure
6(a)). The significant and long-lasting effects of a single
administration of ascending doses of AYX2 were further
confirmed in independent experiments in the SNI and
CCI models (Figure 6(b)–(e)).
Functional relationships associated with KLF6, KLF9,
and KLF15 binding
Binding to KLF9 appears central to a decoy efficacy, in
association with KLF15 binding in the SNI model and
with KLF6 binding in the CCI model. To understand the
functional relationship between the bindings of each
KLF pair, a detailed meta-analysis of in vivo and
in vitro datasets generated during this body of work
was conducted. It was hypothesized that a decoy efficacy
could be driven by either the absolute binding level to its
targets or by a ratio of binding to its targets. To test this,
the average efficacy level of decoys in each pain model
was analyzed as a potential linear function of KLF bind-
ing features. The analyses suggested that in the SNI
model, the efficacy of a decoy is associated with its
KLF15/KLF9 binding ratio (Figure 5(d)):
. If the binding level of KLF15 is similar to the binding
level of KLF9 (i.e., KLF15/KLF9 0.9), the decoy
has no effect.
. If the ratio of KLF15/KLF9 binding is unbalanced, a
decoy efficacy increases as a linear function of
the KLF15/KLF9 binding ratio (i.e., the more
KLF15 binding over KLF9, the higher the efficacy,
R2 0.7).
In the CCI model, the efficacy of a decoy appears in
part correlated with its combined binding capacity to
KLF6þKLF9 (Figure 5(e)):
. The sole binding level to KLF6 (linear regression
coefficient R2 0.3), KLF9 (R2 0.4), or KLF15
(R2 0.3) is not sufficient to explain efficacy.
Table 3. Binding profiles of KLF decoy 1 and 2 variants selected for in vivo testing.
KLF decoy 1 variants KLF decoy 2 variants
Variant decoy name 1.6.2 1.6.5 1.9 2.1 2.5 2.9
Variant decoy size (bp) 25 18 22 15 24 21
Size reduction relative to original decoy (%) 32% 51% 41% 48% 17% 28%
Mean relative
binding efficiency
148% 127% 134% 168% 141% 128%
Binding efficiency KLF6 Mean 102% 65% 135% 94% 125% 146%
relative to original decoy SEM 9% 17% 41% 19% 14% 27%
KLF9 Mean 193% 184% 128% 285% 168% 127%
SEM 10% 40% 8% 116% 14% 15%
KLF15 Mean 150% 131% 138% 125% 130% 111%
SEM 5% 10% 16% 25% 5% 7%
Relative binding efficiency is calculated as the binding of a decoy for a given KLF normalized by its sequence size and the binding efficiency of the decoy it
derives from. Mean relative binding efficiency relates to the combined relative binding efficiency of KLF6, KLF9, and KLF15; n¼ 4 for each testing condition.
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Figure 5. (a) Effect of variants of KLF decoy 1 in the SNI model. Meanþ SEM values of normalized total responses to repetitive von Frey
hairs application for animal groups treated with vehicle (triangle), KLF decoy 1 (X mark), 1.6.5 (white circle), 1.6.2 (square), and 1.9 (black
circle) decoys are displayed. Normalization of von Frey hair responses was performed for each rat individually against its preinjection value
measured on post-surgery day 14, and the corresponding raw von Frey values are presented in supplemental Table 5. Articles were injected
intrathecally once on post-surgery day 14 (arrow); Preinjection data before day 14 are combined across groups, t test versus vehicle:
*p4 0.05, data distribution over the testing period: ANOVA, all groups: p< 0.0001, Dunnett’s multiple comparisons test against vehicle:
p< 0.05 for all comparisons except for decoy 1.9, n¼ 4 per group. This study was performed at AfaSci, Inc. (b) Range of effect of the
variants of KLF decoy 1 in the SNI model. Meanþ SEM values of response for each individual von Frey hair out of five stimulations from the
day of injection until the last day of testing for each decoy plotted from the experiment displayed in (a) above, ref¼ reference, t test versus
vehicle, *p< 0.05, ANOVA for all groups at each hair level from 6 to 26 g: p< 0.05, Dunnett’s multiple comparison test against vehicle:
zp< 0.05. (c) Efficacy pattern of KLF decoys in the SNI and CCI pain models. Mean efficacy values for each decoy tested in the SNI and CCI
models are plotted. Efficacy is calculated as the percentage of reduction of normalized von Frey hair response values compared to vehicle
during the entire testing period (area under the curve) in each study and model, n¼ 4–6 per decoy and model. (d) Linear regression of KLF
decoy’s efficacy in the SNI model in relation to KLF15/KLF9 binding ratio. Efficacy is measured as described in (c) above. When a decoy
efficacy was tested in independent studies, the value used for the plot is an average of the efficacy measured across those studies. Similarly,
when a decoy binding was repeated throughout several phases of the sequence development process, the value used for the plot is an
average of the binding measured across those phases. Each dot represents values of a given decoy, linear regression (red line), coefficient of
linear regression R2 0.7. (e) Linear regression of KLF decoy efficacy in the CCI model in relation to KLF6þKLF9 binding. This plot was
constructed using the principles described in (c). Each dot represents values of a given decoy, coefficient of linear regression R2 0.6.
Studies included in (c), (d), and (e) were performed at the Stanford University and AfaSci, Inc.
CCI: chronic constriction injury; KLF: Kruppel-like transcription factor; SNI: spared nerve injury; VF: von Frey hair.
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Figure 6. (a) Comparison of AYX2 (white bars) and KLF decoy 1 (black bars) binding features for KLF6, KLF9 and KLF15. Meanþ SEM
binding efficiency for each KLF (binding level in OD450 unit divided by the decoy size in bp) is shown in the graph; n5 5. This study was
performed at Adynxx, Inc. (b) Effect of ascending AYX2 doses in the SNI model. Meanþ SEM values of total responses to repetitive von
Frey hair application for groups treated with vehicle (white triangle) or AYX2 50 (black triangle), 100 (X mark), 200 (black circle), or 300
nmoles (white circle) are displayed. In this experiment, the 50-nmole AYX2 dose is considered without effect based on the fact that von
Frey responses remain stable following injection and do not increase nor decrease. Articles were injected intrathecally once on day 14
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. Combining KLF15 binding level to either KLF6 or
KLF9 binding does not alter their respective linear
regression coefficient (i.e., KLF6 R2 0.3
KLF6þKLF15 R2 0.3; KLF9 R2 0.4KLF9þ
KLF15 R2 0.4), suggesting that KLF15 binding
does not play a significant role in this type of pain.
. Efficacy appears to be a linear function of the combined
binding of KLF6þKLF9 (R2 of 1/(KLF6þKLF9)
0.6): the more the binding, the higher the efficacy.
Considering the value level of the regression coefficient,
it is conceivable that other factors potentially independ-
ent of binding activities, such as stability or cellular
uptake influence a decoy’s activity. Collectively, this
meta-analysis shows that the relationships between
KLF9 and KLF15 or KLF9 and KLF6 are different
and work independent of each other.
Discussion
Effects of intrathecal AYX2 and binding to KLF6, KLF9,
and KLF15
Pain is a dynamic state maintained at the genomic level
by dynamic transcriptomes.1,28 A group of transcription
factors with the potential to control these transcriptomes
was selected based on their known functions and gene
promoter’s analysis. The impartial screening of decoys
designed against those factors identified two decoys
that bind to KLF6, KLF9, and KLF15 that significantly
reduced chronic pain following a single administration in
the SNI and CCI models of pain.
Based on prior work using repeat von Frey test-
ing,18,25 the magnitude of von Frey responses at the
time of the decoy treatments reflected a fully developed
mechanical hypersensitization and nociceptive state. In
that context, KLF decoys produced up to 60%–70%
reduction in mechanical hypersensitivity compared to
controls, and the effect lasted until hypersensitivity was
resolving in controls. Based on the correlation between
ELISA binding data and in vivo efficacy levels analyses,
KLF9 binding appears to be the central component of
the trio of KLFs bound by the decoys, in association
with KLF15 binding to treat pain in the SNI model
and with KLF6 binding in the CCI model. The func-
tional relationships between KLF9 binding and binding
to the two other KLFs are not of similar nature, suggest-
ing that different transcriptional mechanics underlie pain
maintenance in the two pain models. This observation is
consistent with head-to-head microarray comparison of
spinal cord gene regulations showing that the amount
and type of genes regulated are principally different in
the SNI and CCI models.29
AYX2 was developed as a KLF decoy drug candidate
with a short size capable to achieve a solubility level
compatible with clinical use. Prior pharmacodynamic,
pharmacokinetic, and metabolism studies in rats with
AYX1 showed that a short decoy, unprotected from
metabolism, acts locally in the DRG and/or the spinal
cord tissues following an intrathecal administra-
tion.18,25,30 Further, this work showed that AYX1 rap-
idly penetrates the DRG and spinal cord following
administration and that cell uptake likely occurs in a
nonspecific fashion in both neurons and glial cells via
endocytic mechanisms.23 Considering the doses used
with AYX2 are similar to AYX1, that both decoys are
of comparable size and unprotected toward metabolism,
an analogous local tissue and cells distribution is antici-
pated. Independent work in mice shows that KLF6,
KLF9, and/or KLF15 are expressed in the DRG and/
or the spinal cord in basal or pathologic nociceptive con-
ditions.31–33 Determining whether AYX2 site of action is
primarily the DRG, the spinal cord or both in the SNI
and CCI models would constitute a next step in the char-
acterization of AYX2 mechanism of action.
Potential roles of KLF6, KLF9, and KLF15
in nociception
Uncovering the potential functions of KLF6, KLF9, and
KLF15 in the DRG and/or spinal cord in relation to
Figure 6. Continued
(arrow), t test versus vehicle: *p4 0.05, data distribution over the testing period: ANOVA, all groups: p< 0.0001, Dunnett’s multiple
comparisons test against vehicle: p< 0.05 for all comparisons, n¼ 4 per group. (c) Range of effect of increasing dose levels of AYX2 in the
SNI model. Meanþ SEM values of response for each individual von Frey hair out of five stimulations over the testing period from the day of
injection until the last day of testing plotted from the experiment displayed in (b) above, t test versus vehicle, *p< 0.05, ANOVA for all
groups at each hair level from 4 to 26 g: p< 0.0005, Dunnett’s multiple comparison test: zp< 0.05. (d) Effect of ascending AYX2 dose levels
in the CCI model. Meanþ SEM values of total responses to repetitive von Frey testing for animals groups treated with vehicle (white
triangle) or AYX2 200 (black circle) or 300 nmoles (white circle) are displayed. Articles were injected intrathecally once on day 14 (arrow),
t test versus vehicle: *p4 0.05, data distribution over the testing period: ANOVA, all groups: p< 0.0001, Dunnett’s multiple comparisons
test against vehicle: p< 0.05 for all comparisons, n¼ 4 per group. (e) Range of effect of increasing dose levels of AYX2 in the CCI model.
Meanþ SEM values of response for each individual von Frey hair out of 5 stimulations over the testing period from the day of injection until
the last day of testing plotted from the experiment displayed in (d) above, t test versus vehicle, *p< 0.05, ANOVA, for all groups at each
hair level from 6 to 26 g: p< 0.05, Dunnett’s multiple comparison test against vehicle: zp< 0.05. Studies presented parts (b)–(e) were
performed at AfaSci, Inc.
KLF: Kruppel-like transcription factor; VF: von Frey hair.
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nociception requires experimental determination and
would be a direct expansion of the work presented here.
However, hypotheses can be drawn based on the known
roles of KLF6, KLF9, and KLF15 in the central nervous
system, and we propose in the section below mechanisms
that could be at play in relation to AYX2 efficacy.
The nociceptive system functions through long-term
potentiation and memory mechanisms similar to the
hippocampus.34 Studies of the hippocampus in KLF9
knockout versus wild-type mice showed that KLF9 is
expressed in neurons and required for neurogenesis-
dependent synaptogenesis in adults.35 Further, KLF9
expression is induced by neuronal activity and regulates
genes involved in synaptic plasticity (e.g., Lin7b, pen-
traxin-2, Nav1.3, Cav3.1, KChip4, KCNA4).
36–42 It is
possible that KLF9 controls the transcriptomes main-
taining synaptic structural rearrangement and hyperex-
citability following injury in the DRG and spinal cord,
two landmark mechanisms of chronic pain. While
KLF15 can be expressed in neurons, KLF15 is sufficient
to induce an astrocyte phenotype and appears to be
mainly expressed in GFAP-positive astrocytes in the
adult spinal cord.32 The fact that AYX2 efficacy is
concurrent with KLF9 and KLF15 binding at a ratio
different from 1 in the SNI model suggests that the
physiological output of KLF9 and KLF15 functions as
a ratio of their respective activities. Similar mechanisms
have been illustrated in endocrine systems, where KLF9
and KLF15 are implicated in feed forward loops and
synergistic transcriptional mechanisms.43 Thus an appro-
priate ratio of transcriptional activity of KLF9 in neu-
rons and KLF15 in astrocytes may be required in the
DRG–spinal cord network for the two cell types to effi-
ciently interact and coordinate the perpetuation of
chronic pain. This may be achieved by locally maintain-
ing high activity levels of bi- (pre- and post-synaptic
neurons) and tri- (including astrocytes) partite synapses.
Such intercellular cross talk would be consistent with
KLF physiology, as illustrated by KLF4 and KLF5
which coordinate epithelial cell proliferation while
being expressed in different cell types.26 In such context,
an hypothesis is that AYX2 treatment could restore the
ratio of KLF15 and KLF9 activities in neurons and
astrocytes to a baseline level, disrupting the pathologic
state of communication between those cells required for
high synaptic activity and chronic pain.
In the CCI model, our data suggest that AYX2 activ-
ity is driven by total binding to KLF6 plus KLF9, inde-
pendent of the ratio of binding, which would indicate
that KLF6 and KLF9 roles are redundant for maintain-
ing chronic pain. Similar functional redundancy has been
demonstrated between KLF6 and KLF7 which can com-
pensate for each other to drive neurite outgrowth.44
Further, multiple KLFs can act as a network to regulate
common intracellular pathways.43 Since KLF9 is
involved in synaptogenesis, one can envision KLF6
and KLF9 both maintaining the synaptic changes
required for neuronal sensitization and pain in the
DRG–spinal cord network. Interestingly, a side-by-side
electrophysiological study of the DRG–spinal cord con-
nectivity in the SNI and CCI models revealed ‘‘divergent
plasticity’’ mechanisms of excitatory synaptic transmis-
sion in the two models.45 This data is consistent with
KLF9 function in synaptic plasticity and suggests that
KLF9 and KLF15 on one hand and KLF9 and KLF6 on
the other hand build distinct modalities of plasticity in
the two models.
KLF6, KLF9, and KLF15 in rodents and human
KLF6, KLF9, and KLF15 are well-conserved ortholog
proteins with 94%, 97%, and 84% protein identity,
respectively, between rat and human forms. Further,
an almost complete conservation is found within their
zinc finger DNA binding sites with sequence identities
ranging from 97% to 100% across the two species
(NCBI accession numbers: NP_113830/NP_001291,
NP_476559/NP_001197, AAH89782/NP_054798).
This structural conservation appears to correlate, at
least in the systems that have been studied below, to a
conservation of function between rodents and human.
For instance, experiments in mice and in human endo-
thelial cells showed that KLF6 promotes vascular
remodeling following an injury in both species.46 Head-
to-head study in mice and human primary hepatocytes
showed that KLF9 was induced by the triiodothyronine
hormone and controlled the downstream hepatocytes
proliferation and differentiation response.47 As for
KLF15, it is upregulated by glucocorticoids in human
and mouse airway smooth muscles and acts as a regula-
tor of airway function, illustrating conservation of both
function and regulation.48,49 This combined information
on the conservation of KLF structure, regulation, and
function supports the potential translation of AYX2
drug candidate effects from rats to human and highlights
KLF6, KLF9, and KLF15 as novel targets for the treat-
ment of pain.
Conclusions
This study shows that KLF decoys binding to KLF6,
KLF9, and KLF15 transcription factors can alleviate
mechanical hypersensitivity in the SNI and CCI rat
models of chronic neuropathic pain. The correlation of
in vitro decoy binding data with in vivo efficacy suggests
KLF9 cooperates in different fashions with KLF6 and
KLF15 depending on the pain etiology, which is consist-
ent with the modus operandi of this large family of inte-
grated transcription factors. AYX2 is an 18-bp long
DNA decoy developed specifically to bind and inhibit
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KLF6, KLF9, and KLF15 locally in the DRG spinal
cord network to produce large and long-lasting relief
of mechanical hypersensitivity following a single intra-
thecal injection. This data support AYX2 therapeutic
potential for treating chronic pain syndromes and con-
stitutes the basis for characterizing further the roles of
the KLF family in nociception.
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